FDA clears Verily’s Study Watch for on-demand ECG

Alphabet‘s (NSDQ:GOOGL) life sciences group, Verily, said today that it won 510(k) clearance from the FDA for its Study Watch for its on-demand electrocardiogram feature.

In a blog post published today, the head of Verily’s cardiovascular health innovations unit, Dr. Michael McConnell, wrote that the Study Watch indication covers the recording, storage, transfer and display of single-channel ECG rhythms.

“The ability to take an on-demand, single-lead ECG, can support both population-based research and an individual’s clinical care,” McConnell wrote. “Receiving this clearance showcases our commitment to the high standards of the FDA for safety and effectiveness and will help us advance the application of Study Watch in various disease areas and future indications. We look forward to embarking on additional research explorations focused on cardiovascular health.”

The post FDA clears Verily’s Study Watch for on-demand ECG appeared first on MassDevice.

from MassDevice http://bit.ly/2RDG4GQ